{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T19:53:35Z","timestamp":1766087615350,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K24AR073317","K08AR075894"],"award-info":[{"award-number":["K24AR073317","K08AR075894"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Dominant mutations in valosin-containing protein (VCP) gene cause an adult onset inclusion body myopathy, Paget\u2019s disease of bone, and frontotemporal dementia also termed multisystem proteinopathy (MSP). The genotype-phenotype relationships in VCP-related MSP are still being defined; in order to understand this better, we investigated the phenotypic diversity and patterns of weakness in the Cure VCP Disease Patient Registry.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Cure VCP Disease, Inc. was founded in 2018 for the purpose of connecting patients with VCP gene mutations and researchers to help advance treatments and cures. Cure VCP Disease Patient Registry is maintained by Coordination of Rare Diseases at Sanford. The results of two questionnaires with a 5-point Likert scale questions regarding to patients\u2019 disease onset, symptoms, and daily life were obtained from 59 participants (28 males and 31 females) between June 2018 and May 2020. Independent of the registry, 22 patients were examined at the Cure VCP Disease annual patient conference in 2019.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>In the questionnaires of the registry, fifty-three patients (90%) reported that they were with inclusion body myopathy, 17 patients (29%) with Paget\u2019s disease of bone, eight patients (14%) with dementia, two patients (3%) with amyotrophic lateral sclerosis, and a patient with parkinsonism. Thirteen patients (22%) reported dysphagia and 25 patients (42%) reported dyspnea on exertion. A self-reported functional rating scale for motor function identified challenges with sit to stand (72%), walking (67%), and climbing stairs (85%). Thirty-five (59%) patients in the registry answered that their quality of life is more than good. As for the weakness pattern of the 22 patients who were evaluated at the Cure VCP Disease annual conference, 50% of patients had facial weakness, 55% had scapular winging, 68% had upper proximal weakness, 41% had upper distal weakness, 77% had lower proximal, and 64% had lower distal weakness.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The Cure VCP Disease Patient Registry is useful for deepening the understanding of patient daily life, which would be a basis to develop appropriate clinical outcome measures. The registry data is consistent with previous studies evaluating VCP patients in the clinical setting. Patient advocacy groups are essential in developing and maintaining disease registries.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13023-020-01551-0","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T11:03:09Z","timestamp":1601377389000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Phenotypic diversity in an international Cure VCP Disease registry"],"prefix":"10.1186","volume":"15","author":[{"given":"Chiseko","family":"Ikenaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew R.","family":"Findlay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Seiffert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Peck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Peck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas E.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey M.","family":"Statland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conrad C.","family":"Weihl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"issue":"5","key":"1551_CR1","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.nmd.2009.01.009","volume":"19","author":"CC Weihl","year":"2009","unstructured":"Weihl CC, Pestronk A, Kimonis VE. Valosin-containing protein disease: inclusion body myopathy with Paget\u2019s disease of the bone and fronto-temporal dementia. Neuromuscul Disord. 2009;19(5):308\u201315.","journal-title":"Neuromuscul Disord"},{"issue":"8","key":"1551_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.nmd.2016.05.017","volume":"26","author":"T Evangelista","year":"2016","unstructured":"Evangelista T, Weihl CC, Kimonis V, Lochm\u00fcller H, Lochm\u00fclle VRD. 215th ENMC international workshop VCP-related multi-system proteinopathy (IBMPFD) 13\u201315 November 2015, Heemskerk, The Netherlands. Neuromuscul Disord. 2016;26(8):535\u201347.","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"1551_CR3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/ng1332","volume":"36","author":"GD Watts","year":"2004","unstructured":"Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet. 2004;36(4):377\u201381.","journal-title":"Nat Genet"},{"issue":"7442","key":"1551_CR4","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature11922","volume":"495","author":"HJ Kim","year":"2013","unstructured":"Kim HJ, Kim NC, Wang YD, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature. 2013;495(7442):467\u201373.","journal-title":"Nature"},{"issue":"8","key":"1551_CR5","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1212\/WNL.0000000000001864","volume":"85","author":"RC Bucelli","year":"2015","unstructured":"Bucelli RC, Arhzaouy K, Pestronk A, et al. SQSTM1 splice site mutation in distal myopathy with rimmed vacuoles. Neurology. 2015;85(8):665\u201374.","journal-title":"Neurology"},{"issue":"4","key":"1551_CR6","doi-asserted-by":"crossref","first-page":"934.e935","DOI":"10.1016\/j.neurobiolaging.2013.09.016","volume":"35","author":"I Le Ber","year":"2014","unstructured":"Le Ber I, Van Bortel I, Nicolas G, et al. hnRNPA21 and hnRNPA1 mutations are rare in patients with \u201cmultisystem proteinopathy\u201d and frontotemporal lobar degeneration phenotypes. Neurobiol Aging. 2014;35(4):934.e935-936.","journal-title":"Neurobiol Aging"},{"issue":"5","key":"1551_CR7","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.neuron.2010.11.036","volume":"68","author":"JO Johnson","year":"2010","unstructured":"Johnson JO, Mandrioli J, Benatar M, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron. 2010;68(5):857\u201364.","journal-title":"Neuron"},{"issue":"20","key":"1551_CR8","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1212\/WNL.0b013e3182929fc3","volume":"80","author":"M Benatar","year":"2013","unstructured":"Benatar M, Wuu J, Fernandez C, et al. Motor neuron involvement in multisystem proteinopathy: implications for ALS. Neurology. 2013;80(20):1874\u201380.","journal-title":"Neurology"},{"issue":"1","key":"1551_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.parkreldis.2011.07.006","volume":"18","author":"N Chan","year":"2012","unstructured":"Chan N, Le C, Shieh P, et al. Valosin-containing protein mutation and Parkinson\u2019s disease. Parkinsonism Relat Disord. 2012;18(1):107\u20139.","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"1551_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1468-1331.2012.03831.x","volume":"20","author":"S Spina","year":"2013","unstructured":"Spina S, Van Laar AD, Murrell JR, et al. Phenotypic variability in three families with valosin-containing protein mutation. Eur J Neurol. 2013;20(2):251\u20138.","journal-title":"Eur J Neurol"},{"issue":"Pt 12","key":"1551_CR11","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1093\/brain\/aws201","volume":"135","author":"ST de Bot","year":"2012","unstructured":"de Bot ST, Schelhaas HJ, Kamsteeg EJ, van de Warrenburg BP. Hereditary spastic paraplegia caused by a mutation in the VCP gene. Brain. 2012;135(Pt 12):e223 (; author reply e224).","journal-title":"Brain"},{"issue":"10","key":"1551_CR12","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1038\/ejhg.2016.42","volume":"24","author":"BP van de Warrenburg","year":"2016","unstructured":"van de Warrenburg BP, Schouten MI, de Bot ST, et al. Clinical exome sequencing for cerebellar ataxia and spastic paraplegia uncovers novel gene-disease associations and unanticipated rare disorders. Eur J Hum Genet. 2016;24(10):1460\u20136.","journal-title":"Eur J Hum Genet"},{"key":"1551_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jns.2017.06.019","volume":"379","author":"PVS Souza","year":"2017","unstructured":"Souza PVS, Bortholin T, Dias RB, et al. New genetic causes for complex hereditary spastic paraplegia. J Neurol Sci. 2017;379:283\u201392.","journal-title":"J Neurol Sci"},{"issue":"Pt 11","key":"1551_CR14","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1093\/brain\/awu224","volume":"137","author":"MA Gonzalez","year":"2014","unstructured":"Gonzalez MA, Feely SM, Speziani F, et al. A novel mutation in VCP causes Charcot\u2013Marie\u2013Tooth Type 2 disease. Brain. 2014;137(Pt 11):2897\u2013902.","journal-title":"Brain"},{"issue":"4","key":"1551_CR15","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.neurol.2018.04.010","volume":"175","author":"WBVR Pinto","year":"2019","unstructured":"Pinto WBVR, Naylor FGM, Chieia MAT, Souza PVS, Oliveira ASB. New findings in facial-onset sensory and motor neuronopathy (FOSMN) syndrome. Rev Neurol (Paris). 2019;175(4):238\u201346.","journal-title":"Rev Neurol (Paris)"},{"issue":"1","key":"1551_CR16","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/mus.24980","volume":"54","author":"M Kazamel","year":"2016","unstructured":"Kazamel M, Sorenson EJ, McEvoy KM, et al. Clinical spectrum of valosin containing protein (VCP)-opathy. Muscle Nerve. 2016;54(1):94\u20139.","journal-title":"Muscle Nerve"},{"issue":"Pt 2","key":"1551_CR17","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/brain\/awl238","volume":"130","author":"CU H\u00fcbbers","year":"2007","unstructured":"H\u00fcbbers CU, Clemen CS, Kesper K, et al. Pathological consequences of VCP mutations on human striated muscle. Brain. 2007;130(Pt 2):381\u201393.","journal-title":"Brain"},{"issue":"6","key":"1551_CR18","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1136\/jnnp-2015-310362","volume":"87","author":"S Figueroa-Bonaparte","year":"2016","unstructured":"Figueroa-Bonaparte S, Hudson J, Barresi R, et al. Mutational spectrum and phenotypic variability of VCP-related neurological disease in the UK. J Neurol Neurosurg Psychiatry. 2016;87(6):680\u20131.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"1551_CR19","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1212\/01.wnl.0000231139.26253.d0","volume":"67","author":"CC Weihl","year":"2006","unstructured":"Weihl CC, Connolly AM, Pestronk A. Valproate may improve strength and function in patients with type III\/IV spinal muscle atrophy. Neurology. 2006;67(3):500\u20131.","journal-title":"Neurology"},{"issue":"9","key":"1551_CR20","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/(SICI)1097-4598(199909)22:9<1265::AID-MUS15>3.0.CO;2-F","volume":"22","author":"M Beck","year":"1999","unstructured":"Beck M, Giess R, W\u00fcrffel W, Magnus T, Ochs G, Toyka KV. Comparison of maximal voluntary isometric contraction and Drachman\u2019s hand-held dynamometry in evaluating patients with amyotrophic lateral sclerosis. Muscle Nerve. 1999;22(9):1265\u201370.","journal-title":"Muscle Nerve"},{"issue":"4","key":"1551_CR21","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/mus.20958","volume":"37","author":"CE Jackson","year":"2008","unstructured":"Jackson CE, Barohn RJ, Gronseth G, Pandya S, Herbelin L, Group MS. Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity. Muscle Nerve. 2008;37(4):473\u20136.","journal-title":"Muscle Nerve"},{"issue":"1","key":"1551_CR22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/cge.13095","volume":"93","author":"E Al-Obeidi","year":"2018","unstructured":"Al-Obeidi E, Al-Tahan S, Surampalli A, et al. Genotype-phenotype study in patients with valosin-containing protein mutations associated with multisystem proteinopathy. Clin Genet. 2018;93(1):119\u201325.","journal-title":"Clin Genet"},{"issue":"5","key":"1551_CR23","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.neurobiolaging.2007.08.009","volume":"30","author":"A Bersano","year":"2009","unstructured":"Bersano A, Del Bo R, Lamperti C, et al. Inclusion body myopathy and frontotemporal dementia caused by a novel VCP mutation. Neurobiol Aging. 2009;30(5):752\u20138.","journal-title":"Neurobiol Aging"},{"key":"1551_CR24","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jns.2016.07.048","volume":"368","author":"A Abrahao","year":"2016","unstructured":"Abrahao A, Abath Neto O, Kok F, et al. One family, one gene and three phenotypes: a novel VCP (valosin-containing protein) mutation associated with myopathy with rimmed vacuoles, amyotrophic lateral sclerosis and frontotemporal dementia. J Neurol Sci. 2016;368:352\u20138.","journal-title":"J Neurol Sci"},{"issue":"4","key":"1551_CR25","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s10072-019-04154-1","volume":"41","author":"L Tremolizzo","year":"2020","unstructured":"Tremolizzo L, Lizio A, Santangelo G, et al. ALS Cognitive Behavioral Screen (ALS-CBS): normative values for the Italian population and clinical usability. Neurol Sci. 2020;41(4):835\u201341.","journal-title":"Neurol Sci"},{"issue":"3","key":"1551_CR26","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3109\/17482961003727954","volume":"11","author":"SC Woolley","year":"2010","unstructured":"Woolley SC, York MK, Moore DH, et al. Detecting frontotemporal dysfunction in ALS: utility of the ALS Cognitive Behavioral Screen (ALS-CBS). Amyotroph Lateral Scler. 2010;11(3):303\u201311.","journal-title":"Amyotroph Lateral Scler"},{"issue":"9","key":"1551_CR27","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.nmd.2018.06.007","volume":"28","author":"J Plewa","year":"2018","unstructured":"Plewa J, Surampalli A, Wencel M, et al. A cross-sectional analysis of clinical evaluation in 35 individuals with mutations of the valosin-containing protein gene. Neuromuscul Disord. 2018;28(9):778\u201386.","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"1551_CR28","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1136\/jnnp-2013-307051","volume":"86","author":"I Nishino","year":"2015","unstructured":"Nishino I, Carrillo-Carrasco N, Argov Z. GNE myopathy: current update and future therapy. J Neurol Neurosurg Psychiatry. 2015;86(4):385\u201392.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1551_CR29","first-page":"1","volume":"28","author":"PVS Souza","year":"2020","unstructured":"Souza PVS, Badia BML, Gon\u00e7alves EA, et al. Hereditary inclusion body myopathy: a clinical and genetic review. Rev Neurocienc. 2020;28:1\u201323.","journal-title":"Rev Neurocienc"},{"issue":"6","key":"1551_CR30","first-page":"1662","volume":"25","author":"KR Wagner","year":"2019","unstructured":"Wagner KR. Facioscapulohumeral muscular dystrophies. Continuum (Minneap Minn). 2019;25(6):1662\u201381.","journal-title":"Continuum (Minneap Minn)"},{"issue":"5","key":"1551_CR31","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1212\/WNL.0000000000000642","volume":"83","author":"TE Lloyd","year":"2014","unstructured":"Lloyd TE, Mammen AL, Amato AA, Weiss MD, Needham M, Greenberg SA. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology. 2014;83(5):426\u201333.","journal-title":"Neurology"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01551-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-020-01551-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01551-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T23:34:12Z","timestamp":1632872052000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01551-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1551"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01551-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"type":"electronic","value":"1750-1172"}],"subject":[],"published":{"date-parts":[[2020,9,29]]},"assertion":[{"value":"24 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Human studies review committee at Washington University School of Medicine in St. Louis (201903027 for patient meeting, 202005191 for analysis of registry data). All the answers of the questionnaire were deidentified and permitted by the participants to use in this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CI, ARF, MS, AP, and, NP declare that they have no competing interests. NEJ receives royalties from the CCMDHI and the CMTHI. He receives research funds from Dyne, AveXis, CSL Behring, Vertex Pharmaceuticals, Fulcrum Therapeutics, ML Bio, Sarepta, and Acceleron Pharma. He has provided consultation for AveXis, AMO Pharma, Strongbridge BioPharma, Acceleron Pharma, Fulcrum Therapeutics, Dyne, Avidity, and Vertex Pharmaceuticals. JMS reports grants and personal fees from Muscular Distrophy Association, FSHD Society, Friends of FSH Research, Dyne, Avidity, Fulcrum, Acceleron, Sarepta, Strongbridge, Genzyme, and PTC. CCW reports grants and personal fees from Sarepta, personal fees from Acceleron, Casma therapeutics, and ML Bio.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"267"}}